Algeria is accelerating efforts to enhance its health sovereignty by fast-tracking a comprehensive local vaccine production project. The goal is to meet national market needs and ensure a stable supply of vaccines included in the national vaccination schedule. The project also aims to explore export opportunities to African markets. This initiative aligns with President Abdelmadjid Tebboune's vision to strengthen national health sovereignty and achieve health independence.
Algerian Minister of Pharmaceutical Industry, Dr. Wassim Qouider, recently met with representatives from German company Syntegon, a global leader in pharmaceutical manufacturing and packaging equipment. The meeting was part of Dr. Qouider's working visit to Germany, accompanied by the General Director of the public company "Saidal" and other officials. The discussions focused on finalizing negotiations for a vaccine production line project for Saidal, including the timeline for delivery and production capacity.
The project is a key component of President Tebboune's strategy to enhance national health sovereignty by producing strategic pharmaceutical products locally. This includes vaccines manufactured in Algeria according to the full production chain, enabling the country to cover its needs as per the approved vaccination schedule. The initiative also aims to build an industrial base capable of controlling various production stages, leveraging technology transfer and expertise.
The project goes beyond meeting local demands, as Saidal aims to export locally produced vaccines to African countries. The company also seeks to benefit from UNICEF's vaccine procurement programs, which could provide an outlet for Algerian products to international markets. This approach represents a bet on developing the national pharmaceutical industry and enhancing its presence beyond borders.
Algeria's efforts involve completing agreements with major international vaccine producers to establish comprehensive manufacturing and technology transfer arrangements. The new production line is expected to be a cornerstone for implementing these partnerships on the ground. By developing its pharmaceutical industry, Algeria aims to strengthen its position in vaccine production and enhance cooperation with African countries.
During his visit, Dr. Qouider inspected the latest manufacturing equipment developed by Syntegon, which features advanced technology and fully automated operating systems. This equipment has not been widely available, with only a limited number of clients having access to it. The minister's visit provided an opportunity to review the equipment and understand its capabilities.
The vaccine production project aligns with Algeria's broader goals to reduce dependence on foreign suppliers and enhance its health sovereignty. By investing in local production capacity, the country aims to ensure a stable supply of essential vaccines and explore export opportunities. This initiative is a significant step towards achieving health independence and strengthening Algeria's position in the pharmaceutical industry.
Key points
- Algeria is pushing forward with a local vaccine production project to enhance health sovereignty and reduce reliance on foreign suppliers.
- The project aims to meet national market needs and explore export opportunities to African markets.
- The initiative aligns with President Abdelmadjid Tebboune's vision to strengthen national health sovereignty and achieve health independence.
